Abstract
BACKGROUND: Pregnant women with chronic myeloid leukemia (CML) can be treated effectively with the tyrosine-kinase inhibitor imatinib, but data regarding fetal and neonatal exposure and safety are limited. CASE: We present a patient with newly diagnosed CML in early pregnancy. Leukapheresis and interferon-a were initiated in the second trimester with limited benefit. Imatinib was subsequently started at 28 weeks of gestation with complete hematologic response within 4 weeks. No significant maternal or neonatal adverse effects were noted, but imatinib and its primary active metabolite concentrated in maternal breast milk and neonatal urine. CONCLUSION: Imatinib is effective for CML in pregnancy, but caution is warranted in light of potentially unrecognized fetal and neonatal effects.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 831-834 |
| Number of pages | 4 |
| Journal | Obstetrics and Gynecology |
| Volume | 129 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2017 |
Fingerprint
ASJC Scopus subject areas
- Obstetrics and Gynecology
Cite this
Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy. / Burwick, Richard; Kuo, Kelly; Brewer, Diana; Druker, Brian.
In: Obstetrics and Gynecology, Vol. 129, No. 5, 2017, p. 831-834.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy
AU - Burwick, Richard
AU - Kuo, Kelly
AU - Brewer, Diana
AU - Druker, Brian
PY - 2017
Y1 - 2017
N2 - BACKGROUND: Pregnant women with chronic myeloid leukemia (CML) can be treated effectively with the tyrosine-kinase inhibitor imatinib, but data regarding fetal and neonatal exposure and safety are limited. CASE: We present a patient with newly diagnosed CML in early pregnancy. Leukapheresis and interferon-a were initiated in the second trimester with limited benefit. Imatinib was subsequently started at 28 weeks of gestation with complete hematologic response within 4 weeks. No significant maternal or neonatal adverse effects were noted, but imatinib and its primary active metabolite concentrated in maternal breast milk and neonatal urine. CONCLUSION: Imatinib is effective for CML in pregnancy, but caution is warranted in light of potentially unrecognized fetal and neonatal effects.
AB - BACKGROUND: Pregnant women with chronic myeloid leukemia (CML) can be treated effectively with the tyrosine-kinase inhibitor imatinib, but data regarding fetal and neonatal exposure and safety are limited. CASE: We present a patient with newly diagnosed CML in early pregnancy. Leukapheresis and interferon-a were initiated in the second trimester with limited benefit. Imatinib was subsequently started at 28 weeks of gestation with complete hematologic response within 4 weeks. No significant maternal or neonatal adverse effects were noted, but imatinib and its primary active metabolite concentrated in maternal breast milk and neonatal urine. CONCLUSION: Imatinib is effective for CML in pregnancy, but caution is warranted in light of potentially unrecognized fetal and neonatal effects.
UR - http://www.scopus.com/inward/record.url?scp=85017091406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017091406&partnerID=8YFLogxK
U2 - 10.1097/AOG.0000000000001972
DO - 10.1097/AOG.0000000000001972
M3 - Article
VL - 129
SP - 831
EP - 834
JO - Obstetrics and Gynecology
JF - Obstetrics and Gynecology
SN - 0029-7844
IS - 5
ER -